<b>⊿</b> ∭ United	FLORIDA M	IEDICAID PRIO	R AUTHORIZAT	ΓΙΟΝ	
Healthcare	Antip	osychotic (< 6 y	/ears of age)		
	-	180-day Maximum	Approval		
Community Plan	N	lote: Form must be com	pleted in full.		
Recipient's Medicaid ID#		Date of Birth (MM/D	D/YYYY)		
			/		
Recipient's Full Name					
Prescriber's Full Name					
Prescriber's NPI					
Prescriber's Phone Number			Prescriber's	Fax Number	
-				-	-
PROVIDER TYPE OR SPECIALTY:			CHILD UNDER STAT	E CARE/CUSTODY:	Yes No
PATIENT: Male	Female	MEDICA	TION REQUEST:	New	Continuation
HEIGHT: in /	cm WEIGHT:	Ibs	/ kgs BMI:	*B	MI %:
					eight/bmi/calculator.html
Antipsychotic Medication/Strength:	Target		Diagnosi	s: ADHD	-
	(check a	oms: Self-Injurious	Benavior	Autism Spectrun Disruptive Behar	vior Disorder
Quantity:	apply)	☐ Irritability ☐ Other		Disruptive Mood	I Dysregulation Disorder
Directions:					
<u> </u>					
Severity of Target Symptoms	🗌 1 Mild	2 Moderate	3 Marked	4 Severe	5 Extreme
Functional Impairment:	1 Mild	2 Moderate	3 Marked	4 Severe	5 Extreme
Previous Therapy (Pharmacologic	al and Non Pharma	acological):			
Have metabolic monitoring labs* (	• •				🗌 Yes 🗌 No
*Official lab results (most recent) must be					
Has an assessment for Tardive Dy				No DISC	US: Yes No
*Official Form or notation (most recent) m					
Monitoring Plan: RTC:			months	TD Screen: q	months
Next appointment date:		-			
Prescriber's Signature:				_ Date:	
REQUIRED FOR REVIEW: All copies of labs. The provider must retain copies of			ns and recent chart no	oles), and the most re	cent copies of related
		41		· · · · · · · · · · · · · · · · · · ·	4-11
Fax this form to 1-866-940-7328		otice: The documents acc legally privileged. If you a			
Pharmacy PA Call Center: 1-800-310-6826		g, distribution, or action ta ave received this informa			
02.01.2025	immediately and ar	rrange for the return or de ansmission by any party o	estruction of these docu	ments. Distribution, rep	production or any
		any party c			

United Healthcare Community Plan

180-day Maximum Approval

Note: Form must be completed in full.

## **Review Criteria**

- The most current antipsychotic prior authorization request form is required for review.
- All relevant sections of the antipsychotic prior authorization form must be complete.
- To calculate the BMI and BMI percentile, the Centers for Disease Control and Prevention (CDC) provides a BMI Calculator for Children and Teens that may be accessed at the following link: <a href="https://www.cdc.gov/healthyweight/bmi/calculator.html">https://www.cdc.gov/healthyweight/bmi/calculator.html</a>
- The evaluation and progress notes must document target symptoms and behaviors.
- Continuation requests require documentation to demonstrate monitoring for movement disorders. Find screening tools (AIMS, DISCUS) at: <u>http://floridabhcenter.org/assessment-scales.html</u>
- Continuation requests require the attachment of the most recent metabolic monitoring labs to include
  - Fasting glucose and fasting lipids.

## **Clinical Notes**

- Psychosocial treatments should precede the use of psychotherapeutic medications and should continue if medications are prescribed.
- Risks and benefits should be carefully considered before prescribing an antipsychotic.
- Prior to starting an antipsychotic medication, baseline measures should be obtained for weight, height, BMI, blood pressure, fasting glucose and fasting lipids.
- Assessments obtained at baseline should be repeated at three months and at least annually to assure safety and efficacy with the use of antipsychotic treatment.
- Fasting glucose and lipids may need to be assessed every six months to provide optimal monitoring in young children.
- Assessment for movement disorders should be performed during the initial titration, at three months and annually.

## Florida Medicaid Clinical Guidelines

Access the following guidelines at http://floridabhcenter.org/index.html:

- Principles of Practice Regarding the Use of Psychotropic Medication in Children Under Age 6
- Florida Medicaid Best Practice Psychotherapeutic Medication Guidelines for Children and Adolescents

**Confidentiality Notice:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.